@phdthesis{Geyer2023,
  author    = {Geyer, Florian},
  title     = {Targeting of M\(_2\) and M\(_4\) Muscarinic Receptor Subtypes with New Dualsteric Ligands},
  doi       = {10.25972/OPUS-27150},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-271506},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2023},
  abstract  = {As part of the parasympathetic nervous system, muscarinic receptors are involved in the regulation of numerous functions in the human body. However, targeting a specific subtype of muscarinic receptors is challenging due to the high degree of similarity within the binding site of the endogenous neurotransmitter acetylcholine. Therefore, this study focused on the investigation of dualsteric ligands. Such hybrid ligands target the orthosteric acetylcholine binding site and, simultaneously, a distinct allosteric binding site. Since allosteric binding regions show significant structural differences throughout muscarinic receptor subtypes, it was aimed to produce selective ligands by means of combination of two pharmacophores in one molecule. Herein, the thienopyridine derivatives LY2033298 and LY2119620 were chosen as allosteric moieties. Based on literature studies, the investigated allosteric modulators were analyzed in terms of adequate attachment points for the combination with an orthosteric agonist. As orthosteric units, muscarinic superagonist iperoxo, xanomeline, and TMA were applied in this work. Since the distance between orthosteric and allosteric moieties plays a crucial role for dualsteric ligand binding, the linker chain length was also varied. Pharmacological investigations of the synthesized hybrid ligands were perfomed via FRET- and BRET-assay measurements.},
  subject      = {GTP-bindende Proteine},
  language  = {en}
}
@phdthesis{Volpato2021,
  author    = {Volpato, Daniela},
  title     = {Bitopic Ligands and their molecular fragments for the study of the M1 Muscarinic Receptor},
  doi       = {10.25972/OPUS-24881},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-248815},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2021},
  abstract  = {The past decades have witnessed the development of new pharmaceutical compounds that modulate receptor function by targeting allosteric sites. Allosteric sites are, by definition, domains topographically distinct from the orthosteric binding pocket where the natural ligand binds. Exploring the possibilities of linking orthosteric and allosteric pharmacophores in one compound to yield 'bitopic' compounds is a strategy derived from the "message-address" concept by Schwyzer , first applied to GPCRs by Portoghese et al. This concept explicitly underlines the orthosteric/allosteric combination, in opposite to the more general umbrella term bivalent. The broad possibilities of bitopic ligands in the pharmaceutical field are under continuous study. Bitopic compounds are promising pharmaceutical tools for taking advantage of the allosteric binding to achieve subtype selectivity while preserving high affinity at the receptor. The development of bitopic ligands, based on the idea of combining high affinity (via orthosteric sites) with high selectivity (via allosteric sites), have led to the development of highly selective bivalent ligands for GPCRs , such as for the opioid receptors , muscarinic acetylcholine receptors (mAChRs), serotonin receptors, cannabinoid receptors, and gonadotropin-releasing hormone receptors. This concept has even been extended to other receptors, for examples nicotinic receptors and other proteins, such as acetylcholinesterases and the tyrosine kinase receptors TrkA and TrkC. The reasons to pursue a bitopic ligand approach are various. An improved affinity for the target GPCR and/or an improved selectivity either at the level of receptor subtype, or at the level of signaling pathway. Another advantage of bitopic ligands over purely allosteric ligands is that the former rely on the appropriate presence of endogenous agonist tone to mediate their effects, whereas a bitopic ligand would engage the orthosteric site irrespective of the presence or absence of endogenous tone. By way of introduction to the hybrid approach, a review of the concept of hybrids compounds targeting the cholinergic system is presented in section A of this thesis. Recent updates in hybrid molecule design as a strategy for selectively addressing multiple target proteins involved in Alzheimer's disease (AD) is here reported . This represents the potential and the growing interest in hybrid compound as pharmacological tools to achieve receptor subtype selectivity and/or, to study the overall functional activity of the receptor. Until now, muscarinic acetylcholine receptors (mAChRs) have proved to be a particularly fruitful receptor model for the development and characterization of bitopic ligands. In this thesis, several examples of new muscarinic bitopic approach are reported in the results section. A study of bipharmacophoric ligands composed of the muscarinic positive allosteric modulators (BQCAderived compounds) linked with chain of various lengths to different orthosteric building blocks is reported in the result part 1. Synthesis and examination of the potential pharmacological characteristic of Oxotremorine-BQCAd compounds and Xanomeline-BQCAd hybrid derivatives are described in results parts 2 and 4, respectively. Moreover, the bitopic concept has even been extended to other proteins, such as acetylcholinesterase. In the result part 5 an overview of the new Tacrine-Xanomeline hybrids aiming to improve the inhibitory potency of the acetylcholinesterase and simultaneously to increase the cholinergic tone, via the xanomelinic portion acting on the M1 receptor is given. A new trivalent approach is presented for the first time to deepen the study of the M1 muscarinic receptor in the result part 6. Moreover, the synthesis of a new series of iperoxo-derived alkane, bis(ammonio)alkane-type and rigidified chain ligands is given in the result part 7 together with some prospects for further research.},
  subject      = {Ligand <Biochemie>},
  language  = {en}
}
@phdthesis{Agnetta2019,
  author    = {Agnetta, Luca},
  title     = {Novel Photoswitchable and Dualsteric Ligands Acting on Muscarinic Acetylcholine Receptors for Receptor Function Investigation},
  doi       = {10.25972/OPUS-18717},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-187170},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2019},
  abstract  = {G protein-coupled receptor research looks out for new technologies to elucidate the complex processes of receptor activation, function and downstream signaling with spatiotemporal resolution, preferably in living cells and organisms. A thriving approach consists in making use of the unsurpassed properties of light, including its high precision in space and time, noninvasiveness and high degree of orthogonality regarding biological processes. This is realized by the incorporation of molecular photoswitches, which are able to effectively respond to light, such as azobenzene, into the structure of a ligand of a given receptor. The muscarinic acetylcholine receptors belong to class A GPCRs and have received special attention in this regard due to their role as a prototypic pharmacological system and their therapeutic potential. They mediate the excitatory and inhibitory effects of the neurotransmitter acetylcholine and thus regulate diverse important biological processes, especially many neurological functions in our brain. In this work, the application of photopharmacological tool compounds to muscarinic receptors is presented, consisting of pharmacophores extended with azobenzene as light-responsive motif. Making use of the dualsteric concept, such photochromic ligands can be designed to bind concomitantly to the orthosteric and allosteric binding site of the receptor, which is demonstrated for BQCAAI (M1) and PAI (M2) and may lead to subtype- and functionalselective photoswitchable ligands, suitable for further ex vivo and in vivo studies. Moreover, photoswitchable ligands based on the synthetic agonist iperoxo were investigated extensively with regard to their photochemical behavior and pharmacological profile, outlining the advantages and challenges of using red-shifted molecular photoswitches, such as tetraortho- fluoro azobenzene. For the first time on a GPCR it was examined, which impact the different substitution pattern has on both the binding and the activity on the M1 receptor. Results show that substituted azobenzenes in photopharmacological compounds (F4-photoiperoxo and F4-iper-azo-iper) not just represent analogs with other photophysical properties but can exhibit a considerably different biological profile that has to be investigated carefully. The achievements gained in this study can give important new insights into the binding mode and time course of activation processes, enabling precise spatial and temporal resolution of the complex signaling pathway of muscarinic receptors. Due to their role as exemplary model system, these findings may be useful for the investigation into other therapeutically relevant GPCRs.},
  subject      = {Muscarinrezeptor},
  language  = {en}
}
@phdthesis{Riad2019,
  author    = {Riad, Noura},
  title     = {The Development of Dualsteric Ligands for the Elucidation of Mode of Activation of Muscarinic Receptors and their Selective Signaling},
  doi       = {10.25972/OPUS-17928},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-179282},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2019},
  abstract  = {GPCRs, particularly muscarinic receptors (mAChRs), are significant therapeutic targets in many physiological conditions. The significance of dualsteric hybrids selectively targeting mAChR subtypes is their great advantage in avoiding undesired side effects. This is attained by exploitation of the high affinity of ligand-binding to the orthosteric site and the structural diversity of the allosteric site to target an individual mAChR subtype, as well as offering signal bias to avoiding undesired transduction pathways. Furthermore, dualsteric targeting of mAChR subtypes helps in the elucidation of the physiological role of each individual mAChR subtype. The first project was the attempt of synthesis of the M2-preferring ligand AFDX-384. AFDX-384 is known to preferentially bind to the M2 receptor subtype as an orthosteric antagonist, with partial interaction with residues in the allosteric site. This project aimed to re-trace the synthesis route of AFDX-384, to open the door to its upscaling and the future synthesis of AFDX-type dualsteric ligands. The multi-step synthesis of AFDX-384 is achieved through the synthesis of its 2 precursors, the chloro acyl derivative VIII and the piperidinyl derivative IV. Upscaled synthesis of the piperidinyl derivative IV was attained. Synthesis of the chloro acyl compound VIII was attempted. Several trials to synthesize the benzopyridodiazepine nucleus as well as its chloro-acylation resulted in the production of the novel crystal structures V and VI. X-ray crystallography was also done for crystallized molecules of the closed-ring benzopyridodiazepine VII that was previously synthesized. Chloro-acylation reactions of compound VII using phosgene seem to be attainable when done using reflux overnight. However, the use of methanol to aid in elution during silica gel column chromatography converted the expected product to the carbamate analogue IX. Hence, further attempts in purification should refrain from the use of methanol. The use of triphosgene instead of phosgene demonstrates a cleaner route for further upscaled synthesis. The second project was the synthesis of dualsteric ligands involving variable orthosteric and allosteric moieties. Four different types of hybrids have been created over multiple steps. Dualsteric ligands have been synthesized using either a phthalimido- or 1,8-naphthalimidopropylamino moiety as the allosteric-binding group, coupled to either N-desmethyl pirenzepine or N-desmethyl clozapine using variable chain lengths. Furthermore, the synthesis of the dualsteric ligands involving N-desmethyl clozapine linked to either the super-agonist iperoxo or acetylcholine, and being connected using variable alkane chain lengths. Several reaction conditions have been investigated throughout the analysis of the optimal condition to conduct the critical final step of synthesis of these dualsteric hybrids, which involves the linking of the two segments of the hybrid together. The optimal method, which produced the least side products and highest yield, was to connect the two intermediates of the compound in absence of base, catalyst or microwaves while stirring at 35 °C for several days using acetonitrile as solvent (silica gel TLC monitoring, 0.2 M aqueous KNO3/MeOH 2:3). The ideal purification methods for the final compounds were found to be either crystallization from the reaction medium or using C18 reverse phase silica gel flash chromatography (using H2O/MeOH solvent system). All the hybrids will be subjected to pharmacological testing using the appropriate FRET assays.},
  subject      = {Muscarinrezeptor},
  language  = {en}
}
@phdthesis{Kauk2018,
  author    = {Kauk, Michael},
  title     = {Investigating the Molecular Mechanism of Receptor Activation at Muscarinic Receptors by Means of Pathway-Specific Dualsteric Ligands and Partial Agonists},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-173729},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2018},
  abstract  = {G protein-coupled receptors (GPCRs) form the biggest receptor family that is encoded in the human genome and represent the most druggable target structure for modern therapeutics respectively future drug development. Belonging to aminergic class A GPCRs muscarinic Acetylcholine receptors (mAChRs) are already now of clinical relevance and are also seen as promising future drug targets for treating neurodegenerative diseases like Alzheimer or Parkinson. The mAChR family consist of five subtypes showing high sequence identity for the endogenous ligand binding region and thus it is challenging until now to selectively activate a single receptor subtype. A well accepted method to study ligand binding, dynamic receptor activation and downstream signaling is the fluorescence resonance energy transfer (FRET) application. Here, there relative distance between two fluorophores in close proximity (<10 nm) can be monitored in a dynamic manner. The perquisite for that is the spectral overlap of the emission spectrum of the first fluorophore with the excitation spectrum of the second fluorophore. By inserting two fluorophores into the molecular receptor structure receptor FRET sensors can serve as a powerful tool to study dynamic receptor pharmacology. Dualsteric Ligands consist of two different pharmacophoric entities and are regarded as a promising ligand design for future drug development. The orthosteric part interacts with high affinity with the endogenous ligand binding region whereas the allosteric part binds to a different receptor region mostly located in the extracellular vestibule. Both moieties are covalently linked. Dualsteric ligands exhibit a dynamic ligand binding. The dualsteric binding position is characterized by a simultaneous binding of the orthosteric and allosteric moiety to the receptor and thus by receptor activation. In the purely allosteric binding position no receptor activation can be monitored. In the present work the first receptor FRET sensor for the muscarinic subtype 1 (M1) was generated and characterized. The M1-I3N-CFP sensor showed an unaltered physiological behavior as well as ligand and concentration dependent responses. The sensor was used to characterize different sets of dualsteric ligands concerning their pharmacological properties like receptor activation. It was shown that the hybrids consisting of the synthetic full agonist iperoxo and the positive allosteric modulator of BQCA type is very promising. Furthermore, it was shown for orthosteric as well as dualsteric ligands that the degree of receptor activation is highly dependent on the length of and the chemical properties of the linker moiety. For dualsteric ligands a bell-shaped activation characteristic was reported for the first time, suggesting that there is an optimal linker length for dualsteric ligands. The gained knowledge about hybrid design was then used to generate and characterize the first photo-switchable dualsteric ligand. The resulting hybrids were characterized with the M1-I3N-CFP sensor and were described as photo-inactivatable and dimmable. In addition to the ligand characterization the ligand application methodology was further developed and improved. Thus, a fragment-based screening approach for dualsteric ligands was reported in this study for the first time. With this approach it is possible to investigate dualsteric ligands in greater detail by applying either single ligand fragments alone or in a mixture of building blocks. These studies revealed the insights that the effect of dualsteric ligands on a GPCR can be rebuild by applying the single building blocks simultaneously. The fragment-based screening provides high potential for the molecular understanding of dualsteric ligands and for future screening approaches. Next, a further development of the standard procedure for measuring FRET by sensitized emission was performed. Under normal conditions single cell FRET is measured on glass coverslips. After coating the coverslips surface with a 20 nm thick gold layer an increased FRET efficiency up to 60 \% could be reported. This finding was validated in different approaches und in different configurations. This FRET enhancement by plasmonic surfaces was until yet unreported in the literature for physiological systems and make FRET for future projects even more powerful.},
  subject      = {G-Protein gekoppelte Rezeptoren},
  language  = {en}
}
@phdthesis{Schramm2018,
  author    = {Schramm, Simon},
  title     = {Synthesis of Dualsteric Muscarinic M\(_1\) Acetylcholine Receptor Ligands and Neuroprotective Esters of Silibinin},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-173592},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2018},
  abstract  = {Alzheimer's disease is a complex network of several pathological hallmarks. These characteristics always occur concomitantly and cannot be taken as distinct features of the disease. While there are hypotheses trying to explain the origin and progression of the illness, none of them is able to pinpoint a definitive cause. This fact challenges researchers not to focus on one individual hallmark but, bearing in mind the big picture, target two or more indications at once. This work, therefore, addresses two of the major characteristics of AD: the cholinergic hypothesis and neurotoxic oxidative stress. The former was achieved by targeting the postsynaptic muscarinic M1 acetylcholine receptor to further investigate its pharmacology, and the latter with the synthesis of neuroprotective natural antioxidant hybrids. The first aim was the design and synthesis of dualsteric agonists of the muscarinic M1 acetylcholine receptor. Activation of this receptor was previously shown to improve AD pathologies like the formation of Aβ and NFTs and protect against oxidative stress and caspase activation. Selectively targeting the M1 receptor is difficult as subtypes M1 - M5 of the muscarinic AChRs largely share the same orthosteric binding pocket. Orthosteric ligands are thus unsuitable for selective activation of one specific subtype. Secondary, allosteric binding sites are more diverse between subtypes. Allosteric ligands are, however, in most cases dependent on an orthosteric ligand to cause downstream signals. Dualsteric ligands thus utilize the characteristics of both orthosteric and allosteric ligands in form of a message-address concept. Bridged by an alkylene-linker, the allosteric part ensures selectivity, whereas the orthosteric moiety initiates receptor activation. Two sets of compounds were synthesised in this sense. In both cases, the orthosteric ligand carbachol is connected to an allosteric ligand via linkers of different chain length. The first set utilizes the selective allosteric M1 agonist TBPB, the second set employs the selective M1 positive allosteric modulator BQCA. Six compounds were obtained in twelve-step syntheses each. For each one, a reference compound lacking the carbachol moiety was synthesised. The dualsteric ligands 1a-c and 2a c were tested in the IP1 assay. The assay revealed that the TBPB-dualsterics 1 are not able to activate the receptor, whereas the respective TBPB-alkyl reference compounds 27 gave signals depending on the length of the alkylene-linker, suggesting allosteric partial agonism of alkyl compounds 27 and no dualsteric binding of the putatively dualsteric compounds 1. The dualsteric BQCA molecules 2, however, activated the receptor as expected. Efficacy of the C5 linked compound 2b was the highest, yet C3 and C8 compounds (2a and 2c) also showed partial agonism. In this case, the reference compounds 31 showed no receptor activation, implying the intended dualsteric binding mode of the BQCA-carbachol compounds 2. Further investigations will be conducted by the working group of Dr. Christian Tr{\"a}nkle at the Department of Pharmacology at the University of Bonn to confirm binding modes and determine affinities as well as selectivity of the synthesised dualsteric compounds. The second project dealt with the design, synthesis and biological evaluation of neuroprotective esters of the flavonolignan silibinin. While silibinin is already a potent antioxidant, it has been observed that the 7-OH group has a pro-oxidative character, making this position attractive for functionalisation. In order to obtain more potent antioxidants, the pro-oxidative position was esterified with other antioxidant moieties like ferulic acid 35 and derivatives thereof. Seventeen esters of silibinin 32, including pure diastereomers of 7 O feruloylsilibinin (43a and 43b) and a cinnamic acid ester of 2,3-dehydrosilibinin 46, were synthesised by regioselective esterification using acyl chlorides under basic conditions. The physicochemical antioxidant properties were assessed in the FRAP assay. This assay revealed no improvement of the antioxidant properties except for 7-O-dihydrosinapinoylsilibinin 39b. These results, however, do not correlate with the neuroprotective properties determined in the HT-22 hippocampal neuronal cell model. The assay showed overadditive neuroprotective effects of the esters exceeding those of its components and equimolar mixtures with the most potent compounds being 7-O-cinnamoylsilibinin 37a, 7-O-feruloylsilibinin 38a and the acetonide-protected caffeic acid ester 40a. These potent Michael system bearing compounds may be considered as "PAINS", but the assays used to assess antioxidant and neuroprotective activities were carefully chosen to avoid false positive readouts. The most potent compounds 37a and 38a, as well as the diastereomers 43a and 43b, were further studied in assays related to AD. In vitro ischemia, inhibition of microglial activation, PC12 cell differentiation and inhibition of Aβ42 and τ protein aggregation assays showed similar results in terms of overadditive effects of the synthesised esters. Moreover, the diastereomers 43a and 43b showed differences in their activities against oxytosis (glutamate-induced apoptosis), inhibition of Aβ42 and τ protein aggregation, and PC12 cell differentiation. The stereospecific effect or mode of action against Aβ42 and τ protein aggregation is more pronounced than that of silybin A (32a) and silybin B (32b) reported in literature and needs to be elucidated in future work. Stability measurements in cell culture medium revealed that the esters do not only get hydrolysed but are partially oxidised to their respective 2,3-dehydrosilibinin esters. Because dehydrosilibinin 45 itself is described as a more potent antioxidant than silibinin 32, 7 O cinnamoyl-2,3-dehydrosilibinin 46 was expected to be even more potent than its un-oxidised counterpart 37a in terms of neuroprotection. The oxytosis assay, however, showed that the neurotoxicity of 46 is much more pronounced, especially at higher concentrations, reducing its neuroprotective potential. Dehydrosilibinin esters are therefore inferior to the silibinin esters for application as neuroprotectants, because of the difficulty of their synthesis and their increased neurotoxicity. A synergistic effect of both species (silibinin and the oxidised form) might, however, be possible or even necessary for the pronounced neuroprotective effects of silibinin esters. As the dehydro-species show distinct neuroprotective properties at low concentrations, their continuous formation over time might make an essential contribution to the overall neuroprotection of the synthesised esters. Due to solubility issues for some of the ester compounds, 7-O-cinnamoylsilibinin 37a was converted into a highly soluble hemisuccinate. The vastly improved solubility of 7 O cinnamoyl-23-O-succinylsilibinin 48 was confirmed in shake-flask experiments. Contrary to expectation, stability examinations showed that the succinyl compound 48 is not cleaved to form 7-O-cinnamoylsilibinin 37a. Neuroprotection assays confirmed that 48 is not a prodrug of the corresponding ester. It was determined that the main site of hydrolysis is the 7-position, cleaving 37 to silibinin 32 and cinnamic acid thus reducing the compound's neuroprotective effects. Nevertheless, the compound still showed neuroprotection at a concentration of 25 µM. The improved solubility might be more beneficial than the higher neuroprotection of the poorly soluble parent compound 37a in vivo. 7 O Cinnamoylsilibinin 37a was further investigated to reduce Aβ25 35 induced learning impairment in mice. While tendencies of improved short-term and long-term memory in the animals were observed, the effects are not yet statistically significant in both Y-maze and passive avoidance tests. A greater number of test subjects is necessary to ensure correctness of the preliminary results presented in this work. However, an effect of ester 37a is observable in vivo, showing blood-brain barrier penetration. The esters synthesised are a novel approach for the treatment of AD as they show strong neuroprotective effects and their hydrolysis products or metabolites are only non-toxic natural products.},
  subject      = {Organische Synthese},
  language  = {en}
}
@phdthesis{Messerer2017,
  author    = {Messerer, Regina},
  title     = {Synthesis of Dualsteric Ligands for Muscarinic Acetylcholine Receptors and Cholinesterase Inhibitors},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-149007},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2017},
  abstract  = {The study is dealing with the synthesis and pharmacological investigation of newly designed dualsteric ligands of muscarinic acetylcholine receptors belonging to the superfamily of G protein-coupled receptors. Such bipharmacophoric ligands combine the advantages of the orthosteric binding site (high-affinity) and of the topographically distinct allosteric binding site (subtype-selectivity) resulting in compounds with reduced side effects. This opens the way to a new therapeutic approach in the treatment of e.g. chronic pain, drug withdrawal, Parkinson`s and Alzheimer`s disease. Furthermore, the newly synthesized dualsteric compounds were pharmacologically investigated in order to get a better understanding of the activation and signaling processes in muscarinic acetylcholine receptors, especially with regard to partial agonism. The development of the "dynamic ligand binding" concept offers new perspectives for ligand binding and signaling at G protein-coupled receptors. GPCRs are no longer considered as simple on/off switches. Dualsteric ligands can bind in a dualsteric pose, reflecting an active receptor state as well as in a purely allosteric binding pose, characterized by an inactive receptor state resulting in partial agonism. The degree of partial agonism depends on the ratio of active versus inactive receptor populations. On this basis, orthosteric/orthosteric hybrid ligands consisting of the antagonist atropine and scopolamine, respectively, as well as of the agonist iperoxo and isoxazole, respectively, linked via different alkyl chain length were synthesized in order to investigate partial agonism (Figure 1). Figure 1: Structures of the synthesized iperoxo/isoxazole-atropine/scopolamine-hybrids. Furthermore, different sets of quaternary and tertiary homodimers consisting either of two iperoxo or two acetylcholine units were synthesized in order to study their extent on partial agonism (Figure 2). The two agonists were connected by varying alkyl chain length. Binding studies on CHO-hM2 cells of the quaternary compounds revealed that dimerization of the agonist results in a loss of potency. The iperoxo-dimers reached higher maximum effects on the Gi- as well as on the Gs pathway in comparison to the acetylcholine-dimers. Besides the choice of the orthosteric building block (potency of the agonist), the alkyl chain length is also crucial for the degree of partial agonism. Figure 2: Structures of the synthesized quat./tert. iperoxo/acetylcholine-homodimers. Quinolone-based hybrids connected to the superagonist iperoxo and to the endogenous ligand acetylcholine, respectively, linked through an alkyl chain of different length were synthesized in order to develop further partial agonists (Figure 3). FRET studies confirmed M1 subtype-selectivity as well as linker dependent receptor response. The greatest positive FRET signal was observed with quinolone-C6-iper resulting from a positive cooperativity between the two separated moieties, alloster and orthoster. However, the corresponding hybrids with a longer linker led to an inverse FRET signal indicating a different binding mode, e.g. purely allosteric, in contrast to the shorter linked hybrids. Furthermore, the flexible alkyl spacer was replaced by a rigidified linker resulting in the hybrid quinolone-rigid-iperoxo (Figure 3). FRET studies on the M1 receptor showed reduced FRET kinetics, resulting from interactions between the bulky linker and the aromatic lid, located between the orthosteric and allosteric binding site. A bitopic binding mode of the rigidified hybrid is presumed. For further clarity, mutational studies are necessary. Figure 3: M1-selective hybrid compounds. Another aim of this work was the design and synthesis of new hybrid compounds, acting as agonists at the M1 and M2 receptor and as inhibitors for AChE and BChE in the context of M. Alzheimer. Several sets of hybrid compounds consisting of different pharmacophoric units (catalytic active site: phthalimide, naphthalimide, tacrine; peripheric anionic site: iperoxo, isoxazole) linked through a polymethylene chain of varying length were synthesized. Tac-C10-iper (Figure 4), consisting of tacrine and the superagonist iperoxo linked by a C10 polymethylene spacer, was found to have excellent anticholinesterase activity for both AChE (pIC50 = 9.81) and BChE (pIC50 = 8.75). Docking experiments provided a structural model to rationalize the inhibitory power towards AChE. Additionally, the tacrine related hybrids showed affinity to the M1 and M2 receptor. Such compounds, addressing more than one molecular target are favorable for multifactorial diseases such as Alzheimer. Figure 4: Structure of the most active compound regarding anticholinesterase activity. In summary, the choice of the pharmacophoric units, their connecting point as well as the nature, length, and flexibility of the linker play an important role for the activity of designed bivalent ligands. A shorter linker length cannot bridge both binding sites simultaneously in contrast to longer linker chains. On the other hand, too long linker chains can result in unwanted steric interactions. Further investigations with respect to structural variations of hybrid compounds, with or without quaternary ammonium groups, are necessary in the light of drug development.},
  subject      = {Cholinesteraseinhibitor},
  language  = {en}
}
@phdthesis{KittisakSripha2003,
  author    = {Kittisak Sripha,},
  title     = {NOVEL HETEROCYCLIC RING SYSTEMS DERIVED FROM CARACURINE V AS LIGANDS FOR THE ALLOSTERIC SITE OF MUSCARINIC M 2 RECEPTORS},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-6841},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2003},
  abstract  = {Die vorliegende Arbeit befasst sich mit dem Gebiet allosterischer Modulation des muscarinischen M2 Rezeptors. Allosterische Liganden beeinflussen das Bindungsverhalten eines orthosterischen Liganden (Agonisten oder Antagonisten) an die klassische Bindungsstelle des muscarinischen Rezeptors, indem sie seine Affinit{\"a}t entweder erh{\"o}hen(positive Kooperativit{\"a}t) oder erniedrigen (negative Kooperativit{\"a}t). Die allosterische Bindungsstelle befindet sich extrazellul{\"a}r am Eingang der Rezeptor-Bindungstasche. Sie ist weniger konserviert als die orthosterische Bindungsdom{\"a}ne, die tiefer im Rezeptorkanal zwischen den sieben transmembranalen Dom{\"a}nen lokalisiert ist. Demzufolge ist die Entwicklung subtyp-spezifischer allosterisch wirkenden Liganden leichter als subtypspezifischer Agonisten oder Antagonisten. Die Subtypselektivit{\"a}t kann dar{\"u}ber hinaus {\"u}ber unterschiedliche Kooperativit{\"a}ten zwischen dem orthosterischen und allosterischen Liganden an verschiedenen muscarinischen Subtypen erreicht werden. Ein am M1-Rezeptor mit Acetylcholin positiv kooperativer allosterer Modulator, der sich an anderen muscarinischen Subtypen neutral kooperativ verh{\"a}lt, k{\"o}nnte z.B. f{\"u}r die Therapie von Morbus Alzheimer eingesetzt werden. Bisquart{\"a}re Ammoniumsalze des Strychnos-Alkaloids Caracurin-V geh{\"o}ren zu den potentesten allosterischen M2-Liganden. Die relative Stellung der aromatischen Indolringe und der Abstand zwischen den positiv geladenen Stickstoffatomen (ca. 10) in dem sehr starren Caracurin-V-Ringsystem definieren den Pharmakophor f{\"u}r potente allosterische Modulatoren. Caracurin-V-Salze sind strukturell sehr verwandt mit den starken Muskelrelaxantien Toxiferin-I und Alcuronium und besitzen vermutlich selbst neuromuskul{\"a}r-blockierende Eigenschaften, was ihre Anwendung in der pharmakologischen Forschung einschr{\"a}nken w{\"u}rde. Reduktion des Caracurin-V-Ringsystems auf die wesentlichen Pharmakophorelemente k{\"o}nnte zu allosterisch wirksamen Verbindungen mit vernachl{\"a}ssigbarer muskelrelaxierender Wirkung f{\"u}hren. Ziel dieser Arbeit war die Synthese und pharmakologische Testung von Derivaten eines neuen, von Caracurin V abgeleiteten, heterocyclischen Ringsystems. Das neue gew{\"u}nscht 6,7,14,15-Tetrahydro[1,5]diazocino[1,2-a:6,5-a]-diindole-Ringsystem(6) wurde in einer intermolekularen N-Alkylierung von zwei Molek{\"u}len Bromethylindol 5 aufgebaut. Die Ausgangsverbindung 5 konnte aus dem Indolylessigs{\"a}uremethylester 3 durch Reduktion der Estergruppe zum Alkohol und anschließende Substitution durch Brom dargestellt werden. Der bekannte Ester 3 wurde ausgehend von Tryptamin erhalten. Die dreistufige Synthese umfasste N-Dibenzylierung, Einf{\"u}hrung der Malonestergruppe am C-2 von Indol und anschließende Demethoxycarbonylierung. Die Totalsynthese des neuen Pentacyclus ist im Schema 24 dargestellt. Die 3D-Struktur des neuen Ringger{\"u}stes konnte mit Hilfe von NMR-Spektroskopie und semiempirischen Rechnungen (AM1) aufgekl{\"a}rt werden. Verbindung 6 liegt in L{\"o}sung in einer verdrehten Wanne-Konformation mit unsymmetrisch angeordneten Seitenketten vor. Um den Einfluss der Seitenkettenl{\"a}nge des neuen Ringsystems auf die allosterische Wirksamkeit zu untersuchen, war es geplannt, die Ethylamin-Gruppen durch Methylamin-Einheiten zu ersetzen. Der entsprechende Syntheseplan bestand darin, das unsubstituierte Ringsystem in einer doppelten Mannich-Reaktion zu aminomethylieren. Der Ausgangsstoff f{\"u}r die Dimerisierung, Bromethylindol 32, wurde aus Indol-2-carbons{\"a}ure hergestellt. Die Synthese umfasste folgende Reaktionsschritte: Reduktion der Carboxylgruppe und Benzoylierung des resultierenden Alkohols, nucleophile Substitution mit Kaliumcyanid, alkalische Hydrolyse des Cyanids zu Indolacetessigs{\"a}ure, erneute Reduktion zum Alkohol und abschließende Substitution mit Brom. Da Dimerisierungsversuche von 32 nur zur Bildung des HBr-Eliminierungsproduktes 33 f{\"u}hrten, wurde das entsprechende Tosylat als Ausgangsstoff eingesetzt. {\"U}berraschenderweise entstand nicht das erwartete Diazocinodiindol-Ringger{\"u}st, sondern ausschließlich ein isomeres, noch nicht bekanntes 6,7,14,15-Tetrahydro-15aH-azocino[1,2-a:6,5-b]diindol-Ringsystem 35. Die Bildung des neuen unsymmetrischen Ringsystems ist auf den ambidenten Charakter des Indolylanions zur{\"u}ckzuf{\"u}hren, das entweder am Sticksoff oder an C3 alkyliert werden kann. Umsetzung von 35 nach Mannich lieferte das bisaminoalkylierte Produkt 37, neben einer kleinen Menge der monoalkylierten Verbindung 36. Die Totalsynthese des zweiten Ringsystems ist im Schema 25 dargestellt. Um potentere Verbindungen zu erhalten, wurden beide Endstufen 6 bzw. 37 mit Methyliodid zu 14 bzw. 38 quaternisiert. 37 wurde zus{\"a}tzlich mit Allylgruppen zu 39 substituiert. Die pharmakologische Testung von 14, 37, und 38 erfolgte {\"u}ber Radioligandbindungsstudien an Membransuspensionen der Herzventrikel des Hausschweins. Der allostere Effekt der Testverbindungen wurde {\"u}ber die Hemmung der Dissoziation von [3H]-N-Methylscopolamin([3H]-NMS) von den damit ges{\"a}ttigten Rezeptoren gemessen. Die erhaltenen EC50,diss-Werte geben die Konzentration des allosteren Modulators an, bei der die [3H]-NMS-Dissoziation auf die H{\"a}lfte des Kontrollwertes reduziert ist. Sie sind ein Maß f{\"u}r die Affinit{\"a}t der Testsubstanzen zur allosterischen Bindungsstelle des M2 Rezeptors. F{\"u}r die einzige Verbindung mit dem Diazocinodiindole-Ringsystem 14 wurde ein EC50,diss-Wert von 54 nM gemessen. Da 14 {\"u}ber vier Benzylsubstituenten verf{\"u}gt, kann seine Bindungsaffinit{\"a}t am besten mit der von Dibenzylcaracurinium-Dibromid verglichen werden, die ganz {\"a}hnlich ist (69 nM). Aufgrund der Tatsache, dass die Verkleinerung des NSubstituenten am Caracurin-V-Ger{\"u}st zur erheblichen Steigerung der allosterischen Potenz f{\"u}hrte, ist zu erwarten, dass der Austausch der volumin{\"o}sen Benzylgruppen von 14 durch z.B. Methyl- oder Allylsubstituenten, eine deutliche Affinit{\"a}tssteigerung bewirken w{\"u}rde. Damit scheint die allosterische Potenz des neuen Ringsystems mindestens genauso gut zu sein, wie die von Caracurin V. Die beiden Vertreter des Azocinodiindol-Ringsystems, 38 und 39, sind bereits mit den Gruppen substituiert, die die beste allosterische Potenz bei dem Caracurin-V-Ringsystem zeigten (Methyl- und Allyl). Ihre EC50,diss-Werte (35 nM f{\"u}r 38, 48 nM f{\"u}r 39) sprechen jedoch f{\"u}r eine ca. 4-fach schw{\"a}chere Bindungsaffinit{\"a}t als die der entsprechenden Caracurine, was vermutlich auf einen anderen Abstand zwischen den quart{\"a}ren Stickstoffatomen und eine andere relative Stellung der Indolaromaten in den beiden Ringsystemen zur{\"u}ckzuf{\"u}hren ist. Anders als die entsprechenden Caracurin-V-Salze, sind 38 und 39 negativ kooperativ mit dem Antagonisten [3H]NMS. Zusammenfassend l{\"a}sst sich feststellen, dass von den beiden neu synthetisierten heterocyclischen Ringsystemen das direkt von Caracurin V abgeleitete Tetrahydro- [1,5]diazocino[1,2-a:6,5-a]diindol eine bessere und vielversprechende Leitstruktur f{\"u}r die Entwicklung neuer potenter allosterischen Liganden des M2-Rezeptors darstellt. Weitere synthetische Arbeiten an dem Ringsystem wie z.B. Variation des Sticksstoffsubstituenten und der Seitenkettenl{\"a}nge sollten zu einer Steigerung der Bindungsaffinit{\"a}t in den subnanomolaren Bereich f{\"u}hren. Dar{\"u}ber hinaus sind die Ergebnisse der pharmakologischen Testung an dem muskul{\"a}ren Typ des nicotinischen Acetylcholinrezeptors abzuwarten.},
  subject      = {Muscarinrezeptor},
  language  = {en}
}